Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Study to Assess the Safety, Tolerability, Feasibility, and Pharmacokinetics of Inhaled RVT-1601 in Preterm Infants at High-risk for Long-term Respiratory Morbidities

NCT04007120 is registered in ClinicalTrials.gov with Respivant Sciences GmbH as lead sponsor.

NCT NCT04007120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04007120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Study to Assess the Safety, Tolerability, Feasibility, and Pharmacokinetics of Inhaled RVT-1601 in Preterm Infants at High-risk for Long-term Respiratory Morbidities
Lead sponsor
Respivant Sciences GmbH
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2019
Completion date
May 29, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory morbidities of prematurity (rmp)